Imbalanced cross-overs [Study Per­for­mance]

posted by khaoula – Algeria, 2014-06-06 18:03 (4402 d 00:08 ago) – Posting: # 13039
Views: 22,518

Hi Helmut,

❝ I don’t understand what you mean here. The limit for HVDs/HVDPs is 30% CV of the reference obtained in a replicate design. CVintra from a 2×2 serves only as a hint of a highly variable reference (since pooled from CVWR and CVWT).


this is a real study that was done in the institute were I do my post graduate disertation, and the drug is omeprazole, that is a HVDP (in bibliography I read a lot of bioequivalence stydy were CV > 30%) I know that the cross over isn't adapted for this, but CV C max of the study Was very low!!!!!!!!

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
136 visitors (0 registered, 136 guests [including 15 identified bots]).
Forum time: 18:11 CEST (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5